Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Roflumilast (Zoryve)

decorative image of the issue cover

Published July 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses roflumilast (Zoryve) foam, 0.3% w/w for topical use, supplied in a 60 g pressurized aluminum can.
  • Indication: For topical treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older.